86 related articles for article (PubMed ID: 25212884)
1. Treatment of transplant-eligible patients with multiple myeloma in 2014.
Landau H; Giralt S
Hematol Oncol Clin North Am; 2014 Oct; 28(5):815-27. PubMed ID: 25212884
[TBL] [Abstract][Full Text] [Related]
2. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Cavo M; Rajkumar SV; Palumbo A; Moreau P; Orlowski R; Bladé J; Sezer O; Ludwig H; Dimopoulos MA; Attal M; Sonneveld P; Boccadoro M; Anderson KC; Richardson PG; Bensinger W; Johnsen HE; Kroeger N; Gahrton G; Bergsagel PL; Vesole DH; Einsele H; Jagannath S; Niesvizky R; Durie BG; San Miguel J; Lonial S;
Blood; 2011 Jun; 117(23):6063-73. PubMed ID: 21447828
[TBL] [Abstract][Full Text] [Related]
3. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.
Vij R; Kumar S; Zhang MJ; Zhong X; Huang J; Dispenzieri A; Abidi MH; Bird JM; Freytes CO; Gale RP; Kindwall-Keller TL; Kyle RA; Landsburg DJ; Lazarus HM; Munker R; Roy V; Sharma M; Vogl DT; Wirk B; Hari PN
Biol Blood Marrow Transplant; 2015 Feb; 21(2):335-41. PubMed ID: 25445028
[TBL] [Abstract][Full Text] [Related]
4. European perspective on multiple myeloma treatment strategies in 2014.
Ludwig H; Sonneveld P; Davies F; Bladé J; Boccadoro M; Cavo M; Morgan G; de la Rubia J; Delforge M; Dimopoulos M; Einsele H; Facon T; Goldschmidt H; Moreau P; Nahi H; Plesner T; San-Miguel J; Hajek R; Sondergeld P; Palumbo A
Oncologist; 2014 Aug; 19(8):829-44. PubMed ID: 25063227
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in silico studies on single versus multiple transplants for multiple myeloma.
Dingli D; Pacheco JM; Dispenzieri A; Hayman SR; Kumar SK; Lacy MQ; Gastineau DA; Gertz MA
Cancer Sci; 2007 May; 98(5):734-9. PubMed ID: 17359286
[TBL] [Abstract][Full Text] [Related]
6. Role of Consolidation and Maintenance.
Kumar AD; Chari A
Hematol Oncol Clin North Am; 2024 Apr; 38(2):421-440. PubMed ID: 38262780
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter?
Fung HC; Nathan S; Maciejewski JJ
Clin Pharmacol; 2010; 2():71-5. PubMed ID: 22291488
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy for multiple myeloma.
McCarthy PL; Palumbo A
Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886
[TBL] [Abstract][Full Text] [Related]
9. Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Moreau P; Hulin C; Facon T
Hematol Oncol Clin North Am; 2014 Oct; 28(5):829-38. PubMed ID: 25212885
[TBL] [Abstract][Full Text] [Related]
10. Relapsed and refractory multiple myeloma: new therapeutic strategies.
Gentili S; Lonial S
Hematol Oncol Clin North Am; 2014 Oct; 28(5):861-90. PubMed ID: 25212887
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Vincent Rajkumar S
Am J Hematol; 2014 Oct; 89(10):999-1009. PubMed ID: 25223428
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
Moreau P; Mary JY; Attal M
Br J Haematol; 2015 Feb; 168(4):605-6. PubMed ID: 25236408
[No Abstract] [Full Text] [Related]
13. Novel targeted agents in the treatment of multiple myeloma.
Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
[TBL] [Abstract][Full Text] [Related]
14. Curing myeloma at last: defining criteria and providing the evidence.
Barlogie B; Mitchell A; van Rhee F; Epstein J; Morgan GJ; Crowley J
Blood; 2014 Nov; 124(20):3043-51. PubMed ID: 25293776
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation for multiple myeloma.
Bensinger W
Hematol Oncol Clin North Am; 2014 Oct; 28(5):891-902. PubMed ID: 25212888
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
17. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Dimopoulos MA; Orlowski RZ; Facon T; Sonneveld P; Anderson KC; Beksac M; Benboubker L; Roddie H; Potamianou A; Couturier C; Feng H; Ataman O; van de Velde H; Richardson PG
Haematologica; 2015 Jan; 100(1):100-6. PubMed ID: 25261096
[TBL] [Abstract][Full Text] [Related]
18. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski RZ; Gercheva L; Williams C; Sutherland H; Robak T; Masszi T; Goranova-Marinova V; Dimopoulos MA; Cavenagh JD; Špička I; Maiolino A; Suvorov A; Bladé J; Samoylova O; Puchalski TA; Reddy M; Bandekar R; van de Velde H; Xie H; Rossi JF
Am J Hematol; 2015 Jan; 90(1):42-9. PubMed ID: 25294016
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma - response to Moreau et al.
Leiba M; Avigdor A
Br J Haematol; 2015 Feb; 168(4):604-5. PubMed ID: 25252030
[No Abstract] [Full Text] [Related]
20. Panobinostat for the treatment of multiple myeloma.
Rajkumar SV
Lancet Oncol; 2014 Oct; 15(11):1178-9. PubMed ID: 25242046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
